Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study

Roberto Cilia, Janeth Laguna, Erica Cassani, Emanuele Cereda, Nicolò G Pozzi, Ioannis U Isaias, Manuela Contin, Michela Barichella, Gianni Pezzoli, Roberto Cilia, Janeth Laguna, Erica Cassani, Emanuele Cereda, Nicolò G Pozzi, Ioannis U Isaias, Manuela Contin, Michela Barichella, Gianni Pezzoli

Abstract

Objective: To investigate whether Mucuna pruriens (MP), a levodopa-containing leguminous plant growing in all tropical areas worldwide, may be used as alternative source of levodopa for indigent individuals with Parkinson disease (PD) who cannot afford long-term therapy with marketed levodopa preparations.

Methods: We investigated efficacy and safety of single-dose intake of MP powder from roasted seeds obtained without any pharmacologic processing. Eighteen patients with advanced PD received the following treatments, whose sequence was randomized: (1) dispersible levodopa at 3.5 mg/kg combined with the dopa-decarboxylase inhibitor benserazide (LD+DDCI; the reference treatment); (2) high-dose MP (MP-Hd; 17.5 mg/kg); (3) low-dose MP (MP-Ld; 12.5 mg/kg); (4) pharmaceutical preparation of LD without DDCI (LD-DDCI; 17.5 mg/kg); (5) MP plus benserazide (MP+DDCI; 3.5 mg/kg); (6) placebo. Efficacy outcomes were the change in motor response at 90 and 180 minutes and the duration of on state. Safety measures included any adverse event (AE), changes in blood pressure and heart rate, and the severity of dyskinesias.

Results: When compared to LD+DDCI, MP-Ld showed similar motor response with fewer dyskinesias and AEs, while MP-Hd induced greater motor improvement at 90 and 180 minutes, longer ON duration, and fewer dyskinesias. MP-Hd induced less AEs than LD+DDCI and LD-DDCI. No differences in cardiovascular response were recorded.

Conclusion: Single-dose MP intake met all noninferiority efficacy and safety outcome measures in comparison to dispersible levodopa/benserazide. Clinical effects of high-dose MP were similar to levodopa alone at the same dose, with a more favorable tolerability profile.

Clinicaltrialsgov identifier: NCT02680977.

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Changes (mean ± standard error)…
Figure 1. Changes (mean ± standard error) in Unified Parkinson’s Disease Rating Scale part III (motor score) at 90 and 180 minutes after treatment intake
DDCI = dopa-decarboxylase inhibitor.

References

    1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374–379.
    1. Cilia R, Akpalu A, Sarfo FS, et al. . The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014;137:2731–2742.
    1. Dotchin C, Msuya O, Kissima J, et al. . The prevalence of Parkinson's disease in rural Tanzania. Mov Disord 2008;23:1567–1672.
    1. Mokaya J, Dotchin C, Gray WK, Hooker J, Wlaker RW. The accessibility of Parkinson's disease medication in Kenya: results of a national survey. Mov Disord Clin Pract 2016;3:376–381.
    1. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa-treatment. Ann Neurol 1987;22:8–12.
    1. Cassani E, Cilia R, Laguna J, et al. . Mucuna pruriens for Parkinson's disease: low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci 2016;365:175–180.
    1. Katzenschlager R, Evans A, Manson A, et al. . Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75:1672–1677.
    1. Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord 2010;16:458–465.
    1. Lieu CA, Venkiteswaran K, Gilmour TP, et al. . The antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evid Based Complement Alternat Med 2012;2012:840247.
    1. Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord 2013;28:566–568.
    1. Kasture S, Mahalaxmi Mohan M, Kasture V. Mucuna pruriens seeds in treatment of Parkinson's disease: pharmacological review. Orient Pharm Exp Med 2013;13:165–174.
    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
    1. Calne DB, Reid JL, Vakil SD, et al. . Idiopathic parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 1971;3:729–732.
    1. Mars H. Modification of levodopa effect by systemic decarboxylase inhibition. Arch Neurol 1973;28:91–95.
    1. Jaffe ME. Clinical studies of carbidopa and L-DOPA in the treatment of Parkinson's disease. In: Yahr MD, ed. Advances in Neurology, vol 2. New York: Raven; 1973:161–172.
    1. Barbeau A. Treatment of Parkinson's disease with L-DOPA and Ro 4-4602: review and present status. In: Yahr MD, ed. Advances in Neurology, vol 2. New York: Raven; 1973.
    1. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with Parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973;2:1459–1462.
    1. Fahn S. “On-off” phenomenon with levodopa therapy in Parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431–441.
    1. Gershanik OS. Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord 2015;30:103–113.
    1. Fahn S, Elton RL; UPDRS Program Members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments Parkinson's Disease, vol 2. Florham Park: Macmillan Healthcare Information; 1987:153–163, 293–304.
    1. Guy W. Abnormal involuntary movement scale: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Government Printing Office; 1976:534–537.
    1. Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997;20:165–167.
    1. Papavasiliou PS, Cotzias GC, Düby SE, Steck AJ, Fehling C, Bell MA. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 1972;286:8–14.
    1. Chase TN, Watanabe AM. Methyldopa hydrazine as an adjunct to L-dopa therapy in parkinsonism. Neurology 1972;22:384–392.
    1. Schwartz AM, Olanow CW, Spencer A. A double-blind controlled study of MK-486 in Parkinson's disease. Trans Am Neurol Assoc 1973;98:301–303.
    1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337–345.
    1. Watanabe AM, Chase TN, Cardon PV. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther 1970;11:740–746.
    1. Calne DB, Petrie A, Rao S, Reid JL, Vakil SD. Action of L-methyldopa-hydrazine on the blood pressure of patients receiving levodopa. Br J Pharmacol 1972;44:162–164.
    1. Marsden CD, Barry PE, Parkes JD, Zilkha KJ. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopa hydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry 1973;36:10–14.
    1. Leibowitz M, Lieberman A. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson’s disease. Neurology 1975;25:917–921.
    1. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2:234–243.
    1. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–2653.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner